ATIMPISTATIN

ATIMPISTATIN is a preclinical-stage recombinant protein therapeutic being developed by BiocurePharm for the treatment of solid tumors. The program has been recognized as a government-funded project in South Korea, focused on discovering optimal clinical indications and conducting preclinical testing to support its commercialization. As a novel biologic candidate, ATIMPISTATIN is designed to inhibit tumor growth and progression, potentially through mechanisms characteristic of endogenous 'statin'-class therapeutic proteins (such as anti-angiogenesis), although its specific molecular target has not been publicly detailed in company pipeline disclosures.